The use of aluminium salts in vaccines has long been a topic of debate. However, a nationwide cohort study conducted in Denmark, which investigated the potential link between cumulative aluminium exposure from early childhood vaccinations and the development of autoimmune, atopic or allergic, and neurodevelopmental disorders, revealed striking results.
The research found no evidence that aluminium in vaccines increases the risk of developing childhood conditions such as asthma, autism, or a host of other autoimmune and neurodevelopmental disorders.
The message is clear - aluminium used to make vaccines more effective does not make them more dangerous.
Not one of the 50 conditions examined, including a broad range of autoimmune, allergic, and neurodevelopmental disorders, occurred at statistically higher rates than expected, effectively ruling out any moderate or significant risk linked to aluminium exposure in vaccines. Senior author Anders Hviid called the findings “quite striking,” reinforcing the study’s strong message that aluminium in vaccines does not pose a measurable threat to children’s health.
“We can exclude meaningful increases with a large degree of certainty for many of these outcomes. We should not be concerned about aluminium used as an adjuvant in childhood vaccines. I think that’s the core message,” said Hviid, who heads the department of epidemiology research at the Statens Serum Institut, Denmark’s public health agency.
